What is the impact factor of Science Translational Medicine?

Science Translational Medicine has an impact factor of 14.6 (2024). This places it among the top-tier journals in its field with This journal exists for one purpose: moving discoveries from the bench to the bedside.

How long does Science Translational Medicine take to review?

Science Translational Medicine typically takes 4-8 weeks for initial decision. The full review process involves 6 main stages: presubmission inquiry (strongly recommended), full manuscript submission, and peer review.

All Journal Guides

Journal Guide

Science Translational Medicine Impact Factor 14.6: Publishing Guide

Q: What is the acceptance rate of Science Translational Medicine?

Science Translational Medicine has an acceptance rate of ~15%. A common reason for rejection is submitting basic science dressed up as translational research. This is the most common reason for desk rejection. Researchers add a paragraph about 'clinical implications' to their Discussion and think that's enough. It isn't. Editors can spot this immediately because the experiments stop where basic science papers typically stop - at the mechanism. There's no biomarker development, no therapeutic testing, no human data. If you haven't actually done translational experiments, don't try to frame it as translational research.

Q: Is Science Translational Medicine peer reviewed?

Yes, Science Translational Medicine is fully peer reviewed. All submissions undergo rigorous peer review by Papers that pass triage go to 2-4 reviewers, typically including both basic scientists and clinicians. Expect detailed questions about clinical feasibility, not just experimental rigor. Reviewers often request additional human validation or more clinically relevant endpoints. The review process is thorough because the stakes of moving research toward patients are high..

Q: What does Science Translational Medicine look for in submissions?

Tangible clinical relevance, not hand-waving: Don't tell editors your work 'may have therapeutic implications.' Show them. If you've identified a target, you'd better have tested an inhibitor. If you've found a biomarker, you'd better have validated it in patient samples. The translational bridge can't just be theoretical - you need to have started building it. Papers that end with 'future clinical studies are warranted' without any preliminary human data usually don't make the cut.

Science Translational Medicine bridges laboratory discoveries and patient care. If your research won't change how doctors treat patients in the next decade, it's probably not right for this journal.

14.6

Impact Factor (2024)

~15%

Acceptance Rate

4-8 weeks for initial decision

Time to First Decision

What Science Translational Medicine Publishes

This journal exists for one purpose: moving discoveries from the bench to the bedside. It's not enough to describe a biological mechanism or identify a new drug target. You've got to show the path forward to human application, and ideally, you've already taken the first steps down that path. Editors want papers that'll change clinical practice, not papers that might theoretically matter someday. The sweet spot is work that's far enough along to be credible but early enough to be novel. Pure basic science goes to Science proper. Late-stage clinical trials often fit better in NEJM or Lancet. STM occupies the middle ground where translation actually happens.

Preclinical studies with clear, validated biomarkers that can be measured in human patients - not just mouse survival curves.
Early-phase clinical trials that demonstrate proof-of-concept for new therapeutic approaches or reveal unexpected biology in humans.
Diagnostic and prognostic tools that've been tested in real patient samples, not just cell lines or archived specimens.
Drug repurposing studies that show a known compound works through a newly understood mechanism with direct clinical implications.
Disease mechanism papers are acceptable but only if they identify a druggable target and show preliminary evidence that targeting it works.

Editor Insight

“I see hundreds of submissions each year, and the pattern of desk rejections is remarkably consistent. Researchers send us excellent basic science with a few paragraphs tacked on about how it might matter for patients someday. That's not what we publish. We want papers where the translation has already started. I'm looking for human data - patient samples, clinical correlations, early trial results - that show your mouse findings aren't just mouse findings. The ideal submission makes me think: this could change clinical practice in five years. If I can't see that path, I won't send it to review. What kills papers isn't lack of rigor or novelty in the traditional sense. It's disconnect from clinical reality. Authors sometimes don't know what treatments patients already receive, or they haven't thought about whether their therapeutic approach is actually developable. We're a bridge journal, but you've got to have started building from both sides of the river.”

What Science Translational Medicine Editors Look For

Tangible clinical relevance, not hand-waving

Don't tell editors your work 'may have therapeutic implications.' Show them. If you've identified a target, you'd better have tested an inhibitor. If you've found a biomarker, you'd better have validated it in patient samples. The translational bridge can't just be theoretical - you need to have started building it. Papers that end with 'future clinical studies are warranted' without any preliminary human data usually don't make the cut.

Mechanistic depth backing up clinical observations

Clinical observations alone won't get you in. If you've run a trial and seen an effect, you need to explain why. What's the molecular mechanism? What's the cellular biology? STM readers are scientists first, and they want to understand how things work, not just that they work. This is what distinguishes the journal from purely clinical outlets. The mechanism needs to be novel and important, not a confirmation of what everyone already suspected.

Multiple model systems and human validation

A finding in one mouse strain won't cut it. Editors want to see consistency across multiple animal models, or better yet, across species. And there needs to be human data - patient samples, clinical correlations, or early trial results that show your findings translate. The whole point of the journal is translation, so you can't stop at the mouse. Human relevance can't be assumed; it must be demonstrated.

Quantitative rigor that can inform clinical decisions

Vague claims about 'significant improvement' don't help anyone design a clinical trial. What's the effect size? What's the therapeutic window? How does efficacy compare to existing treatments? Editors want numbers they can use to calculate sample sizes and predict clinical outcomes. If your preclinical data can't inform a realistic clinical development plan, the paper lacks the quantitative foundation the journal requires.

Novelty that matters for patients

Academic novelty isn't the same as clinical novelty. You might have discovered something no one's ever seen before, but if it doesn't change how we'd diagnose or treat disease, STM isn't interested. Conversely, confirming a therapeutic mechanism with human data might not be academically novel, but it could be exactly what the field needs to move forward. The novelty question is always: does this get us closer to helping patients?

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Science Translational Medicine's editorial review:

Submitting basic science dressed up as translational research

This is the most common reason for desk rejection. Researchers add a paragraph about 'clinical implications' to their Discussion and think that's enough. It isn't. Editors can spot this immediately because the experiments stop where basic science papers typically stop - at the mechanism. There's no biomarker development, no therapeutic testing, no human data. If you haven't actually done translational experiments, don't try to frame it as translational research.

Overrelying on a single animal model without human validation

Mouse models fail in human trials constantly. Editors know this, and they're skeptical of papers that show beautiful results in mice without any human correlation. Even preliminary human data - gene expression from patient samples, correlation with clinical outcomes in existing datasets - dramatically strengthens a paper. Without it, reviewers will ask whether your finding is a mouse artifact or a genuine biological principle.

Burying the translational significance in the Discussion

Your Abstract and Introduction need to make the clinical relevance obvious. If editors have to read to page 15 to understand why this matters for patients, they'll assume it doesn't. Many submissions get desk-rejected because the authors couldn't articulate the translational thesis clearly upfront. Lead with the clinical problem, then explain how your work solves it.

Presenting incremental improvements as breakthroughs

Making an existing treatment 20% better in mice doesn't clear the bar unless you've also shown it works in patients. For preclinical work, the improvement needs to be dramatic enough that it's worth the risk and cost of clinical development. STM isn't interested in marginal gains that would never justify a new clinical trial. The translational path has to make economic and practical sense, not just statistical sense.

Ignoring the existing clinical field

Reviewers will immediately ask: how does this compare to current standard of care? If your new therapeutic approach isn't clearly better than what doctors already use, why would anyone develop it? Papers that ignore existing treatments or fail to benchmark against them suggest the authors don't understand the clinical context. You've got to know what's already being done and explain why your approach is superior.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Science Translational Medicine's criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Science Translational Medicine Authors

Structure your paper around the translational thesis, not the experimental timeline

Most researchers write papers in the order they did experiments. That's backwards for STM. Start with the clinical problem, then show each piece of evidence building toward the solution. The narrative should feel like you're making a case for why this should move into clinical development. Editors respond to papers that read like translational roadmaps.

Include a 'Translational Outlook' or perspective on clinical development

The best STM papers don't just present data - they tell you what should happen next. What clinical trial design makes sense? What patient population should be targeted first? What regulatory hurdles need to be addressed? This demonstrates you've thought beyond the bench and understand what it takes to actually translate findings into practice.

Collaborative author lists signal genuine translation

Papers with both basic scientists and clinicians as authors are viewed more favorably because they suggest real collaboration. If your author list is entirely postdocs from one lab, it raises questions about whether you've engaged with the clinical community. Involving clinicians, even as consultants, strengthens both the science and the perception of translational relevance.

Negative results in human validation can still be publishable

If you show that a promising preclinical finding doesn't hold up in patients, that's valuable information. It saves the field from wasted effort. STM publishes cautionary tales alongside success stories because failed translation is just as informative as successful translation. Don't hide human data that contradicts your mouse results.

Use the Focus article format for disease mechanism papers

If your work is more mechanistic than therapeutic, the Focus format might be more appropriate than a Research Article. Focus pieces allow for more speculation about clinical implications without requiring you to have already done all the translational experiments. It's a good option for early-stage work with strong clinical potential.

The Science Translational Medicine Submission Process

Presubmission inquiry (strongly recommended)

1-2 weeks for response

Send a one-page summary to the editors before submitting your full manuscript. Describe the clinical problem, your approach, key findings, and why it matters for patients. This saves everyone time - you'll learn in a week or two whether your work is appropriate for the journal, rather than waiting months for a desk rejection.

Full manuscript submission

Allow 2-3 hours for submission system

Prepare your manuscript according to AAAS formatting guidelines. Pay close attention to the structured abstract requirements - editors use these to assess fit quickly. Include supplementary materials but don't hide essential translational evidence there. The main text should stand alone in making the case for clinical relevance.

Editorial triage

1-3 weeks

A handling editor assesses scope and significance. About half of submissions are declined at this stage without external review. The most common reason is insufficient translational relevance - the work is too basic or doesn't include human data. If you've done a presubmission inquiry, you've already passed an informal version of this step.

Peer review

4-6 weeks

Papers that pass triage go to 2-4 reviewers, typically including both basic scientists and clinicians. Expect detailed questions about clinical feasibility, not just experimental rigor. Reviewers often request additional human validation or more clinically relevant endpoints. The review process is thorough because the stakes of moving research toward patients are high.

Revision and decision

2-4 weeks for decision after revision

Most accepted papers require revision. Pay careful attention to reviewer concerns about clinical relevance - these aren't optional. If reviewers ask for human validation and you can't provide it, your paper probably won't be accepted. Be realistic about what additional experiments are feasible within the typical 3-6 month revision window.

Production and publication

4-6 weeks from acceptance to publication

Accepted papers go through copyediting and proof stages. STM publishes weekly, so you won't wait long once you're accepted. There's an option for embargo coordination if you're announcing results alongside a clinical trial or regulatory decision. The journal works with authors on timing for maximum impact.

Science Translational Medicine by the Numbers

Impact Factor (2024)(Among the top journals in translational medicine specifically)	14.6
Acceptance Rate(Varies by article type; Research Articles are most competitive)	~15%
Time to First Decision(Faster if desk-rejected; presubmission inquiry adds 1-2 weeks upfront)	4-8 weeks
Annual Publications(Weekly publication schedule with consistent output)	~350 articles
Open Access Option(AAAS offers open access for additional fee; many funders require it)	Available
Altmetric Performance(Papers frequently covered in medical and mainstream press)	High

Before you submit

Science Translational Medicine accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Science Translational Medicine. ~30 minutes.

Run Free Readiness Scan See a sample report

Article Types

Research Article

Up to 5,000 words main text

The flagship format for original research with both mechanistic insight and clinical relevance. Must include human data or have a clear, immediate path to human validation. These are the most competitive submissions.

Research Resource

Up to 5,000 words

Tools, technologies, or datasets that enable translational research. Must demonstrate utility for the broader research community, not just your own lab.

Focus

Up to 4,000 words

Perspective pieces on important translational challenges, including disease mechanisms that point toward therapeutic opportunities. Allows more speculation than Research Articles.

Viewpoint

Up to 2,500 words

Opinion pieces on translational science policy, ethics, or strategy. Not for presenting new data but for shaping how the field thinks about translation.

Editorial

Up to 1,500 words

Invited commentary on significant developments in translational medicine. Typically paired with a Research Article on the same topic.

Landmark Science Translational Medicine Papers

Papers that defined fields and changed science:

Pardoll et al., 2012 - Established the scientific framework for cancer immunotherapy checkpoint blockade that led to multiple FDA approvals
Bhatt et al., 2017 - Demonstrated the microbiome's role in immunotherapy response, changing patient stratification approaches
June et al., 2014 - Published early CAR-T cell therapy results in leukemia patients that preceded FDA approval
Bhattacharya et al., 2021 - Identified transcriptomic signatures predicting COVID-19 severity that informed clinical triage
Bhutani et al., 2019 - Showed CRISPR-based sickle cell therapy feasibility in patient-derived cells, preceding clinical trials

Preparing a Science Translational Medicine Submission?

Get pre-submission feedback from reviewers who've published in Science Translational Medicine and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected

Confidential

Primary Fields

Cancer therapeutics and immunotherapyCardiovascular disease mechanisms and interventionsNeurological and neurodegenerative diseasesInfectious disease and vaccine developmentMetabolic disorders and diabetesGene therapy and genome editing applicationsRegenerative medicine and stem cellsBiomarker discovery and validationDrug delivery and pharmacologyMedical devices and diagnostics

Related Journal Guides

All journal guides

All articles

Ready to submit to Science Translational Medicine?

A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Science Translational Medicine editors look for.

Need field-expert depth? Human review from $1,000